Abstracts tagged "SLE and interferons"

Abstract Number: 698 • 2019 ACR/ARP Annual Meeting
Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus
Ilana Abeles¹ and Vasileios Kyttaris ², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Gene expression studies have previously demonstrated increased Type I interferon α (IFN) inducible genes in peripheral blood mononuclear cells of systemic lupus erythematosus (SLE)…
Abstract Number: 1094 • 2018 ACR/ARHP Annual Meeting
Endogenous Ifnβ Production Is Required for Efficient BCR Crosslinking and Survival of SLE B Cells
John D. Mountz¹, Shanrun Liu², PingAr Yang³, Qi Wu⁴, Bao Luo⁵, W. Winn Chatham⁶ and Hui-Chen Hsu⁴, ¹University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL, ²Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Medcine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Increased type I interferon (IFN) has been shown to affect survival and activation of B cells in SLE. This study investigated novel mechanisms of…
Abstract Number: 1659 • 2017 ACR/ARHP Annual Meeting
Identification of Long Noncoding RNA RP11-2B6.2 As a Positive Regulator through Type I Interferon Pathway in Lupus Nephritis
Yuanjia Tang¹, Zhuojun Liao¹, Zhixin Xue¹, Lingling Wu¹ and Nan Shen^1,2,3,4, ¹Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, ²Center for Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, ⁴Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
Background/Purpose: Long noncoding RNAs (lncRNAs) have recently been identified to be tightly linked to diverse human diseases. Systemic lupus erythematosus (SLE) is a common autoimmune…
Abstract Number: 2575 • 2017 ACR/ARHP Annual Meeting
The Role of Interferon in Autoimmune-Susceptible Ro60 Knockout Mice
Masaoki Kawasumi¹, Daiki Rokunohe¹, Edward Chiou², Xizhang Sun², Lena Tanaka², Sandra L. Wolin³ and Keith B. Elkon⁴, ¹Medicine/Dermatology, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA, ³RNA Biology Laboratory, National Cancer Institute, Frederick, MD, ⁴Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: The Ro60 protein is a prominent autoantigen in systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Anti-Ro antibodies are strongly associated with UV-mediated skin…
Abstract Number: 1082 • 2016 ACR/ARHP Annual Meeting
Type I/II Interferon Commits to Abnormal Expression of Chemokine Receptor on B Cells in Patients with Systemic Lupus Erythematosus
Maiko Yoshikawa¹, Shingo Nakayamada², Satoshi Kubo³, Shigeru Iwata⁴, Kei Sakata⁵, Yusuke Miyazaki³, Kazuhisa Nakano², Kazuyoshi Saito⁶ and Yoshiya Tanaka⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyusyu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan, ⁶University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by an expanded population of peripheral memory B cells. However, little is known about the qualitative abnormality of…
Abstract Number: 1215 • 2016 ACR/ARHP Annual Meeting
Interferon Signature Genes Are Differentially Expressed Between Microscopic Polyangiitis and Systemic Lupus Erythematosus Peripheral Blood Transcriptomes
Aya Kawasaki¹, Daisuke Tsukui², Yuya Kondo³, Yoshitaka Kimura², Kurumi Asako², Hiroshi Furukawa¹, Hajime Kono², Takayuki Sumida⁴ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, ⁴Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Interferon (IFN) signature has been established in the peripheral blood of the patients with systemic lupus erythematosus (SLE) by transcriptome analyses, indicating a role…
Abstract Number: 1827 • 2016 ACR/ARHP Annual Meeting
Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types
Hao Liu¹, Brandon Higgs², William Rees³, Chris Morehouse⁴, Katie Streicher⁵, P Brohawn², G. Illei⁶ and K Ranade², ¹Translational Medicine, Medimmune, LLC, Gaithers, MD, ²MedImmune, Gaithersburg, MD, ³Translational Medicine, Medimmune, LLC, Gaithersburg, MD, ⁴Medimmune, LLC, Gaithers, MD, ⁵Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁶Medimmune, Gaithersburg, MD
Background/Purpose: Type I interferon (IFN) has been implicated in SLE pathogenesis, and the majority of subjects with SLE have elevated expression of type I IFN-inducible…
Abstract Number: 1615 • 2014 ACR/ARHP Annual Meeting
MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE
Bo Qu^1,2, Xiao Han² and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, ³The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose Type I interferon(IFN) is a critical pathogenic factor in Systemic Lupus Erythematosus(SLE) and its associated nephritis, as elevated IFN inducible genes have been found…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].